This trial is completed!
Search for a recruiting clinical trial for your condition
Your journey
1What's a trial
2Find
3Review
4Get in touch
More info
You can access this
clinical trial
if you have
Chronic Obstructive Pulmonary Disease (COPD)
and you are
between 18 and 50
years old
1
This is an early phase trial to determine
the dosage and safety of the new treatment.
Show me locations

The purpose

A single dose study with the inhaled anti-inflammatory agent PF-03715455 to establish if it has anti-inflammatory activity following a challenge with LPS. Inhaled LPS invokes an acute inflammatory response in the lung which can be seen in induced sputum. PH-0797804 is an internal control for the study.

Provided treatments

  • Drug: PF-03715455
  • Drug: PH-797804
  • Drug: Placebo for PF-03715455
  • Drug: Placebo for PH-797804

Locations near you

Unfortunately, there are no recruiting locations near you. Please check the list with all locations below.
Tris trial is registered with FDA with number: NCT01314885. The sponsor of the trial is Pfizer and it is looking for 39 volunteers for the current phase.
Official trial title:
Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, 3-Way Crossover Study To Determine The Effects Of Single Inhaled Doses Of PF-03715455 (20 Mg) And PH-797804 (30 Mg) On Induced Sputum Neutrophils Following Inhaled Lipopolysaccharide (LPS) Challenge In Healthy Volunteers